AgeX Therapeutics, Inc. (AGE) Comparison with companies in other sectors?

AgeX Therapeutics, Inc. has a share price of 2.50M. You can analyze AgeX Therapeutics, Inc. (AGE) competitors across different market sectors through stock heatmaps.

What are AGE's NET and operating margins?

AgeX Therapeutics, Inc. (AGE) operating margin is around -133.44, and net profit margin is approximately -108.80 as of the latest reports.

In what way does AGE's earnings per share (EPS) trend reflect its financial momentum?

AgeX Therapeutics, Inc. (AGE) EPS is -482.53 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for AgeX Therapeutics, Inc. is -0.02, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for AgeX Therapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for AgeX Therapeutics, Inc. like P/E which is -6.11, P/B which is 61.62, and PEG which is 0.001. Compare them with sector averages to evaluate if the stock is priced fairly.

AgeX Therapeutics, Inc.

AGE•AMEX

Healthcare

Biotechnology

$11.10

$-1.50(-11.90%)

AgeX Therapeutics, Inc. (AGE) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-482.53

P/E Ratio

-0.02

ROE

7.50%

Net Margin

-108.80%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$27.76M

Shares OutstandingTotal number of shares issued

$2.50M

Book Value/ShareNet worth per share

$0.16

Revenue/ShareAnnual revenue per share

$0.02

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-482.53

Net MarginNet income as percentage of revenue

-10879.64%

Operating MarginOperating income as percentage of revenue

-13343.71%

ROEReturn on shareholders' equity

750.48%

ROAReturn on total assets

-203.21%

ROCEReturn on capital employed

-414.20%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-2.86

Cash/ShareCash and equivalents per share

$0.60

FCF YieldFree cash flow as percentage of market cap

-103.24%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for AGEFinancial Ratios Analysis details for AGE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for AGESector Benchmarking details for AGE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for AgeX Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of AgeX Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account AgeX Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for AgeX Therapeutics, Inc.

For AgeX Therapeutics, Inc., essential financial indicators include EPS -482.53, PE -0.02, and ROE 7.50. These key ratios reveal insights into AgeX Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare AgeX Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of AgeX Therapeutics, Inc.

Metrics like Net Margin -10879.64% and ROA -203.21% shed light on how well AgeX Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether AgeX Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of AgeX Therapeutics, Inc.

Using ratios such as P/B Ratio 61.62 and PEG Ratio 0.001, investors can assess whether AgeX Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with AgeX Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for AgeX Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.10 and Cash Flow $-2.86, provide a snapshot of AgeX Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like AgeX Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for AgeX Therapeutics, Inc.

Investing in AgeX Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at AgeX Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;